IBI-3009

N/A

Report date: 2025/01/10 11:50:04

Base Information

Drug NameIBI-3009
Drug Alias NameIBI3009IBI-3009
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionDelta-like protein 3 modulatorsDNA topoisomerase I inhibitors
TargetsDelta-like protein 3DNA topoisomerase I
Therapy Area/IndicationsSolid tumoursSmall Cell Lung CarcinomaCarcinoma, Neuroendocrine
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesInnovent Biologics(Suzhou) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesF. Hoffmann-La Roche LtdInnovent Biologics(Suzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursSmall Cell Lung CarcinomaCarcinoma, Neuroendocrine
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A